(Vienna, August 8, 2022, 10:30 a.m. CEST)--An interim analysis of overall survival data from the IMpower010 trial showed an overall survival trend in favor of atezolizumab in the PD-L1 TC > 1% stage ...
Adjuvant icotinib of 12 months versus observation as adjuvant therapy for completely resected EGFR-mutated stage IB non-small-cell lung cancer: 5-year update from CORIN (GASTO1003). Evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results